FDA approves two Dako assays Dako, an Agilent Technologies company, announced it has received approval from the FDA for the addition of Kadcyla in the labeling of two Dako companion diagnostic assays. Kadcyla is Genentech's new medicine for patients with HER2-positive metastatic breast cancer who have received prior treatment with Genentech's cancer medicine Herceptin and a taxane chemotherapy. The two assays are Dako's HercepTest and HER2 IQFISH pharmDx.
Agilent will will no longer include orders in financial reporting Agilent Technologies announced it will no longer report orders in its periodic filings with the SEC or its quarterly earnings press releases, effective immediately. This change reflects feedback from several of the company's largest shareholders, and was also driven by the fact that Agilent was the only company among its peers to report orders. The other financial metrics included in the company's reporting provide comprehensive detail about Agilent's performance.